New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.

Himani Goyal, MD, discusses a case of cataracts and minimally invasive glaucoma surgery (MIGS) combination, highlighting the benefits of this approach in managing both cataracts and glaucoma in a ...

Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

AI-based screening for pediatric DRD is more cost-effective and increases screening rates compared to traditional ECP methods ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).